231 related articles for article (PubMed ID: 30030356)
1. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
Kreil TR; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
[TBL] [Abstract][Full Text] [Related]
2. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
3. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
Johnson SA; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
[TBL] [Abstract][Full Text] [Related]
4. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
Ma J; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration.
O'Donnell S; Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):349-357. PubMed ID: 34911825
[TBL] [Abstract][Full Text] [Related]
6. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
8. Proceedings of the 2009 Viral Clearance Symposium.
Miesegaes G; Bailey M; Willkommen H; Chen Q; Roush D; Blümel J; Brorson K
Dev Biol (Basel); 2010; 133():3-101. PubMed ID: 21516942
[TBL] [Abstract][Full Text] [Related]
9. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
Roush D; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
[TBL] [Abstract][Full Text] [Related]
10. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
Ma J
PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
[TBL] [Abstract][Full Text] [Related]
11. Proceedings of the 2017 Viral Clearance Symposium, Session 1.2: Upstream Mitigation, Part 2-Virus Barrier Filter and HTST.
Chen D; Bolton G
PDA J Pharm Sci Technol; 2018; 72(5):462-469. PubMed ID: 30030355
[TBL] [Abstract][Full Text] [Related]
12. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
14. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
[TBL] [Abstract][Full Text] [Related]
15. Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies.
Reitz S; Schwantes A
PDA J Pharm Sci Technol; 2022; 76(4):297-305. PubMed ID: 34911829
[TBL] [Abstract][Full Text] [Related]
16. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
17. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
18. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
19. Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products.
Yue C; Teitz S; Miyabashi T; Boller K; Lewis-Ximenez LL; Baylis SA; Blümel J
Viruses; 2019 Mar; 11(3):. PubMed ID: 30866548
[TBL] [Abstract][Full Text] [Related]
20. Session 1.1: Viral Clearance Using Traditional, Well-Understood Unit Operations: Low pH and Detergent Viral Inactivation.
Ma J; Roush D
PDA J Pharm Sci Technol; 2016 Sep; 70(5):410-416. PubMed ID: 27516488
[No Abstract] [Full Text] [Related]
[Next] [New Search]
